Tag: Tuning

Posted on

S. Korea’s SUV maker KG Mobility launches special brand for car tuning and customizing parts

S. Korea’s SUV maker KG Mobility launches special brand for car tuning and customizing parts

[Courtesy of KG Mobility]

SEOUL — KG Mobility, previously recognized as Ssangyong Motor, will start a new subsidiary specializing in tuning and customizable elements for autos, targeting South Korea’s tuning vehicle sections market that is projected to arrive at 10.5 trillion won ($7.9 billion) by 2030.

Ssangyong Motor, which commenced organization in South Korea as a modest car workshop established by the late automotive titan Ha Dong-hwan in 1954, obtained a track record as the maker of activity utility cars (SUVs) in the state with most effective-marketing designs this sort of as complete-sized SUVs Korando and Musso. The corporation also provided SUVs as command automobiles for South Korea’s armed forces.

Even so, the company was obtained by many firms which include China’s SAIC Motor and India’s Mahindra soon after the Asian Money Disaster in the late 1990s right before the organization went through a company rehabilitation method to be obtained by KG Team which specializes in mechanical and chemical products in 2021.

KG Mobility said that the company’s subsidiary “KG S&C” will be kick-started off in April targeting the automobile customizing and tuning market place. KG S&C will launch customizable and tuning areas for KG Mobility vehicles as very well as present engineering and customizing products and services for buyers. KG Mobility will also start out a utilised auto profits organization in which the enterprise will invest in again secondhand KG Mobility autos, repair them, and market the vehicles.

South Korea with extremely potent polices on car tuning areas and customized automobiles commenced to loosen the leash during the final few several years in a bid to beef up the country’s domestic automotive market and associated corporations. The transportation ministry started by exempting some 30 rules on tuning parts in 2019 and permitted drivers to personalize their cars as long as the autos passed safety tests. The ministry also authorized pickup vehicles, a single-ton-course trucks, and 1.5-ton-course vans to insert exterior compartments to come to be camper trucks.

KG Mobility’s New Rexton Sports activities Khan pickup truck launched in 2019 is one particular of the pickup truck designs favored by campers who would like to personalize their vehicles into camping motor vehicles. KG S&C will offer customizing products and services primarily based on the pickup truck and other models so that clients can create particular-objective automobiles these as ambulances, emergency cars, and pickup tow vans primarily based on KG’s SUVs.

© Aju Company Day by day & www.ajunews.com Copyright: All components on this website may well not be reproduced, dispersed, transmitted, displayed, released or broadcast with out the authorization from the Aju Information Corporation.

Posted on

How Much Does Tuning A Car Cost?

How Much Does Tuning A Car Cost?

Tuning is a fashionable thought among drivers. Every person likes modifying and enhancing their cars and trucks for much better success, this sort of as elevated efficiency.

How Much Does Tuning A Car Cost

Nevertheless, for most, tuning costs are an vital thought. Right after all, car or truck selling prices are higher sufficient without the need of added expenditures. So, if you have ever wondered just how high-priced items can get, the report will reply this issue and include all there is to tuning. 

Varieties Of Auto Tuning

There are different styles of tuning, relying on what you want to do with the automobile. But, amid other matters, two stand out as the most popular kinds: motor and electric powered tuning.

Engine Tuning

Motor tuning is completed to enhance acceleration, gas efficiency, torque, and power. There are unique sorts of motor tuning, such as:

  • Supercharger and turbocharger installation to boost electrical power
  • Exhaust technique modification to strengthen effectiveness
  • Fuel injection method modification for improved gas efficiency

Electrical Tuning

Electric powered tuning is all about modifying the electrical programs of your auto. This variety of tuning aims at increasing efficiency, managing, and gas efficiency. It will involve putting in aftermarket parts and upgrading electronic factors like sensors or actuators. There are diverse kinds of electric powered tunings, such as:

  • Electrical motor alternative
  • Floor consequences lights set up
  • Headlight enhance

Causes For Vehicle Tuning

There are lots of good reasons to tune a automobile. If you’re into pace and functionality, then raising your engine’s electric power will give you far more electric power at the wheels. This can be carried out by tuning or setting up an aftermarket functionality exhaust process.

If gasoline economy is a concern, porting and polishing the consumption manifold may well assistance lessen the ingestion movement turbulence and increase airflow by your engine’s cylinders. A reliable-to-air intercooler will also boost performance by cooling incredibly hot air right before it enters the cylinder heads, resulting in far better combustion and enhanced horsepower at significant RPMs owing to a lessened compression ratio.

Enhancing suspension factors like coil overs, sway bars, and bushings will drastically enhance how very well the car goes all around corners without compromising stability at better speeds more than bumps. And that is quite essential for street driving!

Tuning is also vital for safety good reasons. Worn-out shocks/struts can induce excessive body roll beneath really hard acceleration and braking scenarios. This could direct them toward skidding in off-road situations these kinds of as rain puddles. Likely for a tune would immediately take care of this problem and protect your driving safety.

Adjusting motor efficiency with aftermarket elements provides you additional manage more than how your vehicle feels on the highway and can help save you income in phrases of gas efficiency and longevity.

Having said that, you need to have to be certain that the upgrades been given won’t bring about complications for you down the line and will give the desired success. For instance, even though changing suspension elements can also make driving safer, you can find no promise that it will make improvements to over-all comfortability after mounted. That is why it is finest to consult with a certified mechanic on these kinds of issues and by no means endeavor Do it yourself tuning unless you know what you are performing.

Price tag Of Tuning A Auto

The price of tuning your car is dependent on your motor vehicle form, how significantly you want to tune it, where you get it carried out, and the style of tuning. But If you happen to be seeking for a primary tune-up and want to hold your auto managing efficiently, be expecting to spend around $200-$400.

Assuming you happen to be searching for more than that, say an engine rebuild or comprehensive functionality improve, which includes all components, assume to spend among $1,000-$10,000 or far more dependent on what kind of performance upgrades are staying produced.

Summary

Tuning your car or truck can be worthwhile, but you should know the fees beforehand. There are several points to take into consideration when tuning a vehicle, these as regardless of whether or not you can do it oneself or if you will want to fork out somebody else to do that for you. 

There are a lot of good reasons and strategies to tune your automobile, but it is significant to know what you happen to be obtaining into. If you want extra electrical power or superior gasoline economic system, go for it, but do not be expecting miracles. Assure that any funds you spend will be well worth the investment. That way, when your automobile starts off running better than at any time, you will know it was well worth all the hard work.

Posted on

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility | Journal of Translational Medicine

Tuning CARs: recent advances in modulating chimeric antigen receptor (CAR) T cell activity for improved safety, efficacy, and flexibility | Journal of Translational Medicine

  • Cartellieri M, Feldmann A, Koristka S, Arndt C, Loff S, Ehninger A, et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts. Blood Cancer J. 2016;6(8):e458.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, et al. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. 2015;3(4):356–67.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Cruz CR, Hanley PJ, Liu H, Torrano V, Lin YF, Arce JA, et al. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience. Cytotherapy. 2010;12(6):743–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Morgan RA, Yang JC, Kitano M, Dudley ME, Laurencot CM, Rosenberg SA. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther. 2010;18(4):843–51.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014;20(2):112–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Gross G, Eshhar Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu Rev Pharmacol Toxicol. 2016;56:59–83.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Fisher J, Abramowski P, Wisidagamage Don ND, Flutter B, Capsomidis A, Cheung GW, et al. Avoidance of on-target off-tumor activation using a co-stimulation-only chimeric antigen receptor. Mol Ther. 2017;25(5):1234–47.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, et al. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017;130(21):2295–306.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Neelapu SS, Tummala S, Kebriaei P, Wierda W, Gutierrez C, Locke FL, et al. Chimeric antigen receptor T-cell therapy—assessment and management of toxicities. Nat Rev Clin Oncol. 2018;15(1):47–62.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tokarew N, Ogonek J, Endres S, von Bergwelt-Baildon M, Kobold S. Teaching an old dog new tricks: next-generation CAR T cells. Br J Cancer. 2019;120(1):26–37.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Sharma N, Reagan PM, Liesveld JL. Cytopenia after CAR-T cell therapy—a brief review of a complex problem. Cancers. 2022;14(6):1501.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wallet F, Sesques P, Devic P, Levrard M, Ader F, Friggeri A, et al. CAR-T cell: toxicities issues: mechanisms and clinical management. Bull Cancer. 2021;108(10S):S117-27.

    Article 
    PubMed 

    Google Scholar     

  • Zhang K, Chen H, Li F, Huang S, Chen F, Li Y. Bright future or blind alley? CAR-T cell therapy for solid tumors. 2023. https://www.genome.jp/kegg/. Accessed 28 Feb 2023.

  • Yu S, Yi M, Qin S, Wu K. Next generation chimeric antigen receptor T cells: safety strategies to overcome toxicity. Mol Cancer. 2019;18(1):125.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Andrea AE, Chiron A, Bessoles S, Hacein-Bey-Abina S. Engineering next-generation CAR-T cells for better toxicity management. Int J Mol Sci. 2020;21(22):8620.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Mao R, Kong W, He Y. The affinity of antigen-binding domain on the antitumor efficacy of CAR T cells: moderate is better. Front Immunol. 2022;13:1032403.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wu Y, Huang Z, Harrison R, Liu L, Zhu L, Situ Y, Wang Y. Engineering CAR T cells for enhanced efficacy and safety. APL Bioeng. 2022;6:11502. https://doi.org/10.1063/5.0073746.

    Article 
    CAS 

    Google Scholar     

  • Madderson O, Teixeira AP, Fussenegger M. Emerging mammalian gene switches for controlling implantable cell therapies. Curr Opin Chem Biol. 2021;1(64):98–105.

    Article 

    Google Scholar     

  • Feldmann A, Arndt C, Koristka S, Berndt N, Bergmann R, Bachmann MP. Conventional CARs versus modular CARs. Cancer Immunol Immunother. 2019;68(10):1713–9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Arndt C, Fasslrinner F, Loureiro LR, Koristka S, Feldmann A, Bachmann M. Adaptor CAR platforms-next generation of T cell-based cancer immunotherapy. Cancers. 2020;12(5):1302.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Liu D, Zhao J, Song Y. Engineering switchable and programmable universal CARs for CAR T therapy. J Hematol Oncol. 2019;12(1):69.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Sutherland AR, Owens MN, Geyer CR. Modular chimeric antigen receptor systems for universal CAR T cell retargeting. Int J Mol Sci. 2020;21(19):7222.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Gamboa L, Zamat AH, Kwong GA. Synthetic immunity by remote control. Theranostics. 2020;10(8):3652–67.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zheng Y, Nandakumar KS, Cheng K. Optimization of CAR-T cell-based therapies using small-molecule-based safety switches. J Med Chem. 2021;64(14):9577–91.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Miao L, Zhang J, Huang B, Zhang Z, Wang S, Tang F, et al. Special chimeric antigen receptor (CAR) modifications of T cells: a review. Front Oncol. 2022;12:832765.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: recognition and management. Blood. 2016;127(26):3321–30.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Sahillioglu AC, Schumacher TN. Safety switches for adoptive cell therapy. Curr Opin Immunol. 2022;74:190–8.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Caliendo F, Dukhinova M, Siciliano V. Engineered cell-based therapeutics: synthetic biology meets immunology. Front Bioeng Biotechnol. 2019;7:43.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • van Schandevyl S, Kerre T. Chimeric antigen receptor T-cell therapy: design improvements and therapeutic strategies in cancer treatment. Acta Clin Belg. 2020;75(1):26–32.

    Article 
    PubMed 

    Google Scholar     

  • Heard A, Chang J, Warrington JM, Singh N. Advances in CAR design. Best Pract Res Clin Haematol. 2021;34(3):101304.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zajc CU, Salzer B, Taft JM, Reddy ST, Lehner M, Traxlmayr MW. Driving CARs with alternative navigation tools—the potential of engineered binding scaffolds. FEBS J. 2021;288(7):2103–18.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tahmasebi S, Elahi R, Khosh E, Esmaeilzadeh A. Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy. Clin Transl Oncol. 2021;23(6):1003–19.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Mi J, Ye Q, Min Y. Advances in nanotechnology development to overcome current roadblocks in CAR-T therapy for solid tumors. Front Immunol. 2022;13:849759.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Safarzadeh Kozani P, Naseri A, Mirarefin SMJ, Salem F, Nikbakht M, Evazi Bakhshi S, et al. Nanobody-based CAR-T cells for cancer immunotherapy. Biomark Res. 2022;10(1):24.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kyte JA. Strategies for improving the efficacy of CAR T cells in solid cancers. Cancers. 2022;14(3):571.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Schaft N. The landscape of CAR-T cell clinical trials against solid tumors—a comprehensive overview. Cancers. 2020;12(9):2567.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Karlsson H, Svensson E, Gigg C, Jarvius M, Olsson-Stromberg U, Savoldo B, et al. Evaluation of intracellular signaling downstream chimeric antigen receptors. PLoS ONE. 2015;10(12):e0144787.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Sadelain M, Riviere I, Riddell S. Therapeutic T cell engineering. Nature. 2017;545(7655):423–31.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Brenner MJ, Cho JH, Wong NML, Wong WW. Synthetic biology: immunotherapy by design. Annu Rev Biomed Eng. 2018;20:95–118.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64–73.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • MacKay M, Afshinnekoo E, Rub J, Hassan C, Khunte M, Baskaran N, et al. The therapeutic landscape for cells engineered with chimeric antigen receptors. Nat Biotechnol. 2020;38(2):233–44.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Park CH. Making potent CAR T cells using genetic engineering and synergistic agents. Cancers. 2021;13(13):3236.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Chuang ST, Conklin B, Stein JB, Pan G, Lee KB. Nanotechnology-enabled immunoengineering approaches to advance therapeutic applications. Nano Convergence. 2022;9(1):1–31. https://doi.org/10.1186/s40580-022-00310-0.

    Article 
    CAS 

    Google Scholar     

  • Jones BS, Lamb LS, Goldman F, di Stasi A. Improving the safety of cell therapy products by suicide gene transfer. Front Pharmacol. 2014;5:254.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Tey SK. Adoptive T-cell therapy: adverse events and safety switches. Clin Transl Immunol. 2014;3(6):e17.

    Article 

    Google Scholar     

  • Resetca D, Neschadim A, Medin JA. Engineering hematopoietic cells for cancer immunotherapy: strategies to address safety and toxicity concerns. J Immunother. 2016;39(7):249–59.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Straathof KC, Pule MA, Yotnda P, Dotti G, Vanin EF, Brenner MK, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood. 2005;105(11):4247–54.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Berger C, Flowers ME, Warren EH, Riddell SR. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107(6):2294–302.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hakem R, Hakem A, Duncan GS, Henderson JT, Woo M, Soengas MS, et al. Differential requirement for caspase 9 in apoptotic pathways in vivo. Cell. 1998;94(3):339–52.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tiberghien P. Use of suicide genes in gene therapy. J Leukoc Biol. 1994;56(2):203–9.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Beltinger C, Fulda S, Kammertoens T, Meyer E, Uckert W, Debatin KM. Herpes simplex virus thymidine kinase/ganciclovir-induced apoptosis involves ligand-independent death receptor aggregation and activation of caspases. Proc Natl Acad Sci USA. 1999;96(15):8699–704.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Spencer DM, Belshaw PJ, Chen L, Ho SN, Randazzo F, Crabtree GR, et al. Functional analysis of Fas signaling in vivo using synthetic inducers of dimerization. Curr Biol. 1996;6(7):839–47.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Introna M, Barbui AM, Bambacioni F, Casati C, Gaipa G, Borleri G, et al. Genetic modification of human T cells with CD20: a strategy to purify and lyse transduced cells with anti-CD20 antibodies. Hum Gene Ther. 2000;11(4):611–20.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kao RL, Truscott LC, Chiou TT, Tsai W, Wu AM, de Oliveira SN. A cetuximab-mediated suicide system in chimeric antigen receptor-modified hematopoietic stem cells for cancer therapy. Hum Gene Ther. 2019;30(4):413–28.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wang Q, He F, He W, Huang Y, Zeng J, Zi F, et al. A transgene-encoded truncated human epidermal growth factor receptor for depletion of anti- B-cell maturation antigen CAR-T cells. Cell Immunol. 2021;363:104342.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Freytag SO, Khil M, Stricker H, Peabody J, Menon M, DePeralta-Venturina M, et al. Phase I study of replication-competent adenovirus-mediated double suicide gene therapy for the treatment of locally recurrent prostate cancer. Cancer Res. 2002;62(17):4968–76.

    CAS 
    PubMed 

    Google Scholar     

  • Tone Y, Kawahara M, Kawaguchi D, Ueda H, Nagamune T. Death signalobody: inducing conditional cell death in response to a specific antigen. Hum Gene Ther Methods. 2013;24(3):141–50.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wiebking V, Patterson JO, Martin R, Chanda MK, Lee CM, Srifa W, et al. Metabolic engineering generates a transgene-free safety switch for cell therapy. Nat Biotechnol. 2020;38(12):1441–50.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wu X, Shi B, Zhang J, Shi Z, Di S, Fan M, et al. A fusion receptor as a safety switch, detection, and purification biomarker for adoptive transferred T cells. Mol Ther. 2017;25(10):2270–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Shaw T, Quan J, Totoritis MC. B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience. Ann Rheum Dis. 2003;62(Suppl 2):ii55-9.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Putyrski M, Schultz C. Protein translocation as a tool: the current rapamycin story. FEBS Lett. 2012;586(15):2097–105.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Bonini C, Bordignon C. Potential and limitations of HSV-TK-transduced donor peripheral blood lymphocytes after allo-BMT. Hematol Cell Ther. 1997;39(5):273–4.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Tiberghien P. Use of suicide gene-expressing donor T-cells to control alloreactivity after haematopoietic stem cell transplantation. J Intern Med. 2001;249(4):369–77.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ciceri F, Bonini C, Stanghellini MT, Bondanza A, Traversari C, Salomoni M, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study. Lancet Oncol. 2009;10(5):489–500.

    Article 
    PubMed 

    Google Scholar     

  • Traversari C, Marktel S, Magnani Z, Mangia P, Russo V, Ciceri F, et al. The potential immunogenicity of the TK suicide gene does not prevent full clinical benefit associated with the use of TK-transduced donor lymphocytes in HSCT for hematologic malignancies. Blood. 2007;109(11):4708–15.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Casucci M, di Nicolis Robilant B, Falcone L, Camisa B, Norelli M, Genovese P, et al. CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma. Blood. 2013;122(20):3461–72.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Riddell SR, Elliott M, Lewinsohn DA, Gilbert MJ, Wilson L, Manley SA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2(2):216–23.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Lupo-Stanghellini MT, Provasi E, Bondanza A, Ciceri F, Bordignon C, Bonini C. Clinical impact of suicide gene therapy in allogeneic hematopoietic stem cell transplantation. Hum Gene Ther. 2010;21(3):241–50.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Preuss E, Muik A, Weber K, Otte J, von Laer D, Fehse B. Cancer suicide gene therapy with TK.007: superior killing efficiency and bystander effect. J Mol Med. 2011;89(11):1113–24.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997;91(4):479–89.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Duong MT, Collinson-Pautz MR, Morschl E, Lu A, Szymanski SP, Zhang M, et al. Two-dimensional regulation of CAR-T cell therapy with orthogonal switches. Mol Ther Oncolytics. 2019;12:124–37.

    Article 
    PubMed 

    Google Scholar     

  • Lu YJ, Chu H, Wheeler LW, Nelson M, Westrick E, Matthaei JF, et al. Preclinical evaluation of bispecific adaptor molecule controlled folate receptor CAR-T cell therapy with special focus on pediatric malignancies. Front Oncol. 2019;9:151.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lipus A, Janosz E, Ackermann M, Hetzel M, Dahlke J, Buchegger T, et al. Targeted integration of inducible caspase-9 in Human iPSCs allows efficient in vitro clearance of iPSCs and iPSC-macrophages. Int J Mol Sci. 2020;21(7):2481.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Quintarelli C, Vera JF, Savoldo B, Giordano Attianese GM, Pule M, Foster AE, et al. Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes. Blood. 2007;110(8):2793–802.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • de Witte MA, Jorritsma A, Swart E, Straathof KC, de Punder K, Haanen JB, et al. An inducible caspase 9 safety switch can halt cell therapy-induced autoimmune disease. J Immunol. 2008;180(9):6365–73.

    Article 
    PubMed 

    Google Scholar     

  • Diaconu I, Ballard B, Zhang M, Chen Y, West J, Dotti G, et al. Inducible caspase-9 selectively modulates the toxicities of CD19-specific chimeric antigen receptor-modified T cells. Mol Ther. 2017;25(3):580–92.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hoyos V, Savoldo B, Quintarelli C, Mahendravada A, Zhang M, Vera J, et al. Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety. Leukemia. 2010;24(6):1160–70.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • di Stasi A, Tey SK, Dotti G, Fujita Y, Kennedy-Nasser A, Martinez C, et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N Engl J Med. 2011;365(18):1673–83.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Budde LE, Berger C, Lin Y, Wang J, Lin X, Frayo SE, et al. Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma. PLoS ONE. 2013;8(12):e82742.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhou X, Dotti G, Krance RA, Martinez CA, Naik S, Kamble RT, et al. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation. Blood. 2015;125(26):4103–13.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Gargett T, Brown MP. The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells. Front Pharmacol. 2014;5:235.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fan L, Freeman KW, Khan T, Pham E, Spencer DM. Improved artificial death switches based on caspases and FADD. Hum Gene Ther. 1999;10(14):2273–85.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Thomis DC, Marktel S, Bonini C, Traversari C, Gilman M, Bordignon C, et al. A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. Blood. 2001;97(5):1249–57.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Junker K, Koehl U, Zimmerman S, Stein S, Schwabe D, Klingebiel T, et al. Kinetics of cell death in T lymphocytes genetically modified with two novel suicide fusion genes. Gene Ther. 2003;10(14):1189–97.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Berger C, Blau CA, Huang ML, Iuliucci JD, Dalgarno DC, Gaschet J, et al. Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model. Blood. 2004;103(4):1261–9.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Philip B, Kokalaki E, Mekkaoui L, Thomas S, Straathof K, Flutter B, et al. A highly compact epitope-based marker/suicide gene for easier and safer T-cell therapy. Blood. 2014;124(8):1277–87.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Valton J, Guyot V, Boldajipour B, Sommer C, Pertel T, Juillerat A, et al. A versatile safeguard for chimeric antigen receptor T-cell immunotherapies. Sci Rep. 2018;8(1):8972.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Mosti L, Langner LM, Chmielewski KO, Arbuthnot P, Alzubi J, Cathomen T. Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Ther. 2021;28(9):602–12.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91(17):8302–6.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Trinh QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res. 1995;55(21):4808–12.

    CAS 
    PubMed 

    Google Scholar     

  • Hoganson DK, Batra RK, Olsen JC, Boucher RC. Comparison of the effects of three different toxin genes and their levels of expression on cell growth and bystander effect in lung adenocarcinoma. Cancer Res. 1996;56(6):1315–23.

    CAS 
    PubMed 

    Google Scholar     

  • Kuriyama S, Masui K, Sakamoto T, Nakatani T, Kikukawa M, Tsujinoue H, et al. Bystander effect caused by cytosine deaminase gene and 5-fluorocytosine in vitro is substantially mediated by generated 5-fluorouracil. Anticancer Res. 1998;18(5A):3399–406.

    CAS 
    PubMed 

    Google Scholar     

  • Sakemura R, Terakura S, Watanabe K, Julamanee J, Takagi E, Miyao K, et al. A tet-on inducible system for controlling CD19-chimeric antigen receptor expression upon drug administration. Cancer Immunol Res. 2016;4(8):658–68.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Gu X, He D, Li C, Wang H, Yang G. Development of inducible CD19-CAR T cells with a tet-on system for controlled activity and enhanced clinical safety. Int J Mol Sci. 2018;19(11):3455.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Drent E, Poels R, Mulders MJ, van de Donk N, Themeli M, Lokhorst HM, et al. Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design. PLoS ONE. 2018;13(5):e0197349.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ali Hosseini Rad SM, Poudel A, Tan GMY, McLellan AD. Optimisation of tet-on inducible systems for sleeping beauty-based chimeric antigen receptor (CAR) applications. Sci Rep. 2020;10(1):13125.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Ramirez-Garza SL, Laveriano-Santos EP, Marhuenda-Munoz M, Storniolo CE, Tresserra-Rimbau A, Vallverdu-Queralt A, et al. Health effects of resveratrol: results from human intervention trials. Nutrients. 2018;10(12):1892.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Yang L, Yin J, Wu J, Qiao L, Zhao EM, Cai F, et al. Engineering genetic devices for in vivo control of therapeutic T cell activity triggered by the dietary molecule resveratrol. Proc Natl Acad Sci USA. 2021;118(34):e2106612118.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kotter B, Engert F, Krueger W, Roy A, Rawashdeh WA, Cordes N, et al. Titratable pharmacological regulation of CAR T cells using zinc finger-based transcription factors. Cancers. 2021;13(19):4741.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Niopek D, Benzinger D, Roensch J, Draebing T, Wehler P, Eils R, et al. Engineering light-inducible nuclear localization signals for precise spatiotemporal control of protein dynamics in living cells. Nat Commun. 2014;5:4404.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Taslimi A, Zoltowski B, Miranda JG, Pathak GP, Hughes RM, Tucker CL. Optimized second-generation CRY2-CIB dimerizers and photoactivatable Cre recombinase. Nat Chem Biol. 2016;12(6):425–30.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Huang Z, Wu Y, Allen ME, Pan Y, Kyriakakis P, Lu S, et al. Engineering light-controllable CAR T cells for cancer immunotherapy. Sci Adv. 2020;6(8):eaay9209.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pan Y, Yoon S, Sun J, Huang Z, Lee C, Allen M, et al. Mechanogenetics for the remote and noninvasive control of cancer immunotherapy. Proc Natl Acad Sci USA. 2018;115(5):992–7.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Miller IC, Zamat A, Sun LK, Phuengkham H, Harris AM, Gamboa L, et al. Enhanced intratumoural activity of CAR T cells engineered to produce immunomodulators under photothermal control. Nat Biomed Eng. 2021. https://doi.org/10.1038/s41551-021-00781-2.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wu Y, Liu Y, Huang Z, Wang X, Jin Z, Li J, et al. Control of the activity of CAR-T cells within tumours via focused ultrasound. Nat Biomed Eng. 2021. https://doi.org/10.1038/s41551-021-00779-w.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Juillerat A, Marechal A, Filhol JM, Valogne Y, Valton J, Duclert A, et al. An oxygen sensitive self-decision making engineered CAR T-cell. Sci Rep. 2017;7:39833.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Prinzing B, Krenciute G. Hypoxia-inducible CAR expression: an answer to the on-target/off-tumor dilemma? Cell Rep Med. 2021;2(4):100244.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Liao Q, He H, Mao Y, Ding X, Zhang X, Xu J. Engineering T cells with hypoxia-inducible chimeric antigen receptor (HiCAR) for selective tumor killing. Biomark Res. 2020;8(1):56.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kosti P, Opzoomer JW, Larios-Martinez KI, Henley-Smith R, Scudamore CL, Okesola M, et al. Hypoxia-sensing CAR T cells provide safety and efficacy in treating solid tumors. Cell Rep Med. 2021;2(4):100227.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Yang Z-J, Yu Z-Y, Cai Y-M, Du R-R, Cai L. Engineering of an enhanced synthetic Notch receptor by reducing ligand-independent activation. Commun Biol. 2020;3(1):116.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Morsut L, Roybal KT, Xiong X, Gordley RM, Coyle SM, Thomson M, et al. Engineering customized cell sensing and response behaviors using synthetic notch receptors. Cell. 2016;164(4):780–91.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Roybal KT, Rupp LJ, Morsut L, Walker WJ, McNally KA, Park JS, et al. Precision tumor recognition by T cells with combinatorial antigen-sensing circuits. Cell. 2016;164(4):770–9.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Chen LC, Hou AJ, Chen YY. Getting better mileage with logically primed CARs. Med. 2021;2(7):785–7.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Srivastava S, Salter AI, Liggitt D, Yechan-Gunja S, Sarvothama M, Cooper K, et al. Logic-gated ROR1 chimeric antigen receptor expression rescues T cell-mediated toxicity to normal tissues and enables selective tumor targeting. Cancer Cell. 2019;35(3):489-503.e8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Moghimi B, Muthugounder S, Jambon S, Tibbetts R, Hung L, Bassiri H, et al. Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma. Nat Commun. 2021;12(1):511.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Choe JH, Watchmaker PB, Simic MS, Gilbert RD, Li AW, Krasnow NA, et al. SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. www.humanproteomemap.org. Accessed 7 Feb 2023.

  • Hyrenius-Wittsten A, Su Y, Park M, Garcia JM, Alavi J, Perry N, et al. SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Sci Transl Med. 2021;13(591):eabd8836.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Juillerat A, Tkach D, Busser BW, Temburni S, Valton J, Duclert A, et al. Modulation of chimeric antigen receptor surface expression by a small molecule switch. BMC Biotechnol. 2019;19(1):44.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Cao YJ, Wang X, Wang Z, Zhao L, Li S, Zhang Z, et al. Switchable CAR-T cells outperformed traditional antibody-redirected therapeutics targeting breast cancers. ACS Synth Biol. 2021;10(5):1176–83.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Carbonneau S, Sharma S, Peng L, Rajan V, Hainzl D, Henault M, et al. An IMiD-inducible degron provides reversible regulation for chimeric antigen receptor expression and activity. Cell Chem Biol. 2021;28(6):802-812.e6.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Jan M, Scarfo I, Larson RC, Walker A, Schmidts A, Guirguis AA, et al. Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide. Sci Transl Med. 2021;13(575):eabb6295.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Sievers QL, Gasser JA, Cowley GS, Fischer ES, Ebert BL. Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4(CRBN) activity. Blood. 2018;132(12):1293–303.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lee SM, Kang CH, Choi SU, Kim Y, Hwang JY, Jeong HG, et al. A chemical switch system to modulate chimeric antigen receptor T cell activity through proteolysis-targeting chimaera technology. ACS Synth Biol. 2020;9(5):987–92.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Wu CY, Roybal KT, Puchner EM, Onuffer J, Lim WA. Remote control of therapeutic T cells through a small molecule-gated chimeric receptor. Science. 2015;350(6258):aab4077.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Leung WH, Gay J, Martin U, Garrett TE, Horton HM, Certo MT, et al. Sensitive and adaptable pharmacological control of CAR T cells through extracellular receptor dimerization. JCI Insight. 2019;5:e124430.

    Article 
    PubMed 

    Google Scholar     

  • Zajc CU, Dobersberger M, Schaffner I, Mlynek G, Puhringer D, Salzer B, et al. A conformation-specific ON-switch for controlling CAR T cells with an orally available drug. Proc Natl Acad Sci USA. 2020;117(26):14926–35.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Salzer B, Schueller CM, Zajc CU, Peters T, Schoeber MA, Kovacic B, et al. Engineering AvidCARs for combinatorial antigen recognition and reversible control of CAR function. Nat Commun. 2020;11(1):4166.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Juillerat A, Marechal A, Filhol JM, Valton J, Duclert A, Poirot L, et al. Design of chimeric antigen receptors with integrated controllable transient functions. Sci Rep. 2016;6:18950.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Nguyen N, Huang K, Zeng H, Jing J, Wang R, Fang S, et al. Nano-optogenetic engineering of CAR T cells for precision immunotherapy with enhanced safety. Nat Nanotechnol. 2021;16:1–11.

    Article 

    Google Scholar     

  • Sahillioglu AC, Toebes M, Apriamashvili G, Gomez R, Schumacher TN. CRASH-IT switch enables reversible and dose-dependent control of TCR and CAR T-cell function. Cancer Immunol Res. 2021;9(9):999–1007.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Giordano-Attianese G, Gainza P, Gray-Gaillard E, Cribioli E, Shui S, Kim S, et al. A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy. Nat Biotechnol. 2020;38(4):426–32.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Hotblack A, Kokalaki EK, Palton MJ, Cheung GW, Williams IP, Manzoor S, et al. Tunable control of CAR T cell activity through tetracycline mediated disruption of protein-protein interaction. Sci Rep. 2021;11(1):21902.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Park S, Pascua E, Lindquist KC, Kimberlin C, Deng X, Mak YSL, et al. Direct control of CAR T cells through small molecule-regulated antibodies. Nat Commun. 2021;12(1):710.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fedorov VD, Themeli M, Sadelain M. PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses. Sci Transl Med. 2013;5(215):215ra172.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Hamburger AE, DiAndreth B, Cui J, Daris ME, Munguia ML, Deshmukh K, et al. Engineered T cells directed at tumors with defined allelic loss. Mol Immunol. 2020;128:298–310.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Hwang MS, Mog BJ, Douglass J, Pearlman AH, Hsiue EH, Paul S, et al. Targeting loss of heterozygosity for cancer-specific immunotherapy. Proc Natl Acad Sci USA. 2021;118(12):e2022410118.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Tao L, Farooq MA, Gao Y, Zhang L, Niu C, Ajmal I, et al. CD19-CAR-T cells bearing a KIR/PD-1-based inhibitory CAR eradicate CD19(+)HLA-C1(-) malignant B cells while sparing CD19(+)HLA-C1(+) healthy B cells. Cancers. 2020. https://doi.org/10.3390/cancers12092612.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Fei F, Rong L, Jiang N, Wayne AS, Xie J. Targeting HLA-DR loss in hematologic malignancies with an inhibitory chimeric antigen receptor. Mol Ther. 2021. https://doi.org/10.1016/j.ymthe.2021.11.013.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Richards RM, Zhao F, Freitas KA, Parker KR, Xu P, Fan A, et al. NOT-gated CD93 CAR T cells effectively target aml with minimized endothelial cross-reactivity. Blood Cancer Discov. 2021;2(6):648–65.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Aoyama S, Yasuda S, Watanabe D, Akiyama H, Umezawa Y, Nogami A, et al. A novel protease-mediated chimeric antigen receptor (CAR): “Double-Arm” CAR-T cell system improves target specificity of CAR-T cell therapy. Blood. 2019;134(Supplement_1):1941. https://doi.org/10.1182/blood-2019-121973.

    Article 

    Google Scholar     

  • Clemenceau B, Congy-Jolivet N, Gallot G, Vivien R, Gaschet J, Thibault G, et al. Antibody-dependent cellular cytotoxicity (ADCC) is mediated by genetically modified antigen-specific human T lymphocytes. Blood. 2006;107(12):4669–77.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kudo K, Imai C, Lorenzini P, Kamiya T, Kono K, Davidoff AM, et al. T lymphocytes expressing a CD16 signaling receptor exert antibody-dependent cancer cell killing. Cancer Res. 2014;74(1):93–103.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ochi F, Fujiwara H, Tanimoto K, Asai H, Miyazaki Y, Okamoto S, et al. Gene-modified human alpha/beta-T cells expressing a chimeric CD16-CD3zeta receptor as adoptively transferable effector cells for anticancer monoclonal antibody therapy. Cancer Immunol Res. 2014;2(3):249–62.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • D’Aloia MM, Caratelli S, Palumbo C, Battella S, Arriga R, Lauro D, et al. T lymphocytes engineered to express a CD16-chimeric antigen receptor redirect T-cell immune responses against immunoglobulin G-opsonized target cells. Cytotherapy. 2016;18(2):278–90.

    Article 
    PubMed 

    Google Scholar     

  • Tamada K, Geng D, Sakoda Y, Bansal N, Srivastava R, Li Z, et al. Redirecting gene-modified T cells toward various cancer types using tagged antibodies. Clin Cancer Res. 2012;18(23):6436–45.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kim MS, Ma JS, Yun H, Cao Y, Kim JY, Chi V, et al. Redirection of genetically engineered CAR-T cells using bifunctional small molecules. J Am Chem Soc. 2015;137(8):2832–5.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Cao Y, Rodgers DT, Du J, Ahmad I, Hampton EN, Ma JS, et al. Design of switchable chimeric antigen receptor T cells targeting breast cancer. Angew Chem Int Ed Engl. 2016;55(26):7520–4.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Ma JS, Kim JY, Kazane SA, Choi SH, Yun HY, Kim MS, et al. Versatile strategy for controlling the specificity and activity of engineered T cells. Proc Natl Acad Sci USA. 2016;113(4):E450-8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Zhang B, Wang Y, Huang S, Sun J, Wang M, Ma W, et al. Photoswitchable CAR-T cell function in vitro and in vivo via a cleavable mediator. Cell Chem Biol. 2021;28(1):60-69.e7.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Kobayashi A, Nobili A, Neier SC, Sadiki A, Distel R, Zhou ZS, et al. Light-controllable binary switch activation of CAR T cells. ChemMedChem. 2022;17:e202100722.

    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Urbanska K, Powell DJ. Development of a novel universal immune receptor for antigen targeting: to Infinity and beyond. Oncoimmunology. 2012;1(5):777–9.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Urbanska K, Lanitis E, Poussin M, Lynn RC, Gavin BP, Kelderman S, et al. A universal strategy for adoptive immunotherapy of cancer through use of a novel T-cell antigen receptor. Cancer Res. 2012;72(7):1844–52.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lohmueller JJ, Ham JD, Kvorjak M, Finn OJ. mSA2 affinity-enhanced biotin-binding CAR T cells for universal tumor targeting. Oncoimmunology. 2017;7(1):e1368604.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Dale GL, Gaddy P, Pikul FJ. Antibodies against biotinylated proteins are present in normal human serum. J Lab Clin Med. 1994;123(3):365–71.

    CAS 
    PubMed 

    Google Scholar     

  • Grote S, Mittelstaet J, Baden C, Chan KC, Seitz C, Schlegel P, et al. Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting. Oncoimmunology. 2020;9(1):1825177.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Seitz CM, Mittelstaet J, Atar D, Hau J, Reiter S, Illi C, et al. Novel adapter CAR-T cell technology for precisely controllable multiplex cancer targeting. Oncoimmunology. 2021;10(1):2003532.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Werchau N, Kotter B, Criado-Moronati E, Gosselink A, Cordes N, Lock D, et al. Combined targeting of soluble latent TGF-ss and a solid tumor-associated antigen with adapter CAR T cells. Oncoimmunology. 2022;11(1):2140534.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Rodgers DT, Mazagova M, Hampton EN, Cao Y, Ramadoss NS, Hardy IR, et al. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies. Proc Natl Acad Sci USA. 2016;113(4):E459-68.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Viaud S, Ma JSY, Hardy IR, Hampton EN, Benish B, Sherwood L, et al. Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory. Proc Natl Acad Sci USA. 2018;115(46):E10898-906.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Raj D, Yang MH, Rodgers D, Hampton EN, Begum J, Mustafa A, et al. Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma. Gut. 2019;68(6):1052–64.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Landgraf KE, Williams SR, Steiger D, Gebhart D, Lok S, Martin DW, et al. convertibleCARs: a chimeric antigen receptor system for flexible control of activity and antigen targeting. Commun Biol. 2020;3(1):296.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Herzig E, Kim KC, Packard TA, Vardi N, Schwarzer R, Gramatica A, et al. Attacking latent HIV with convertibleCAR-T cells, a highly adaptable killing platform. Cell. 2019;179(4):880-894.e10.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Qi J, Tsuji K, Hymel D, Burke TR Jr, Hudecek M, Rader C, et al. Chemically programmable and switchable CAR-T therapy. Angew Chem Int Ed Engl. 2020;59(29):12178–85.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Minutolo NG, Sharma P, Poussin M, Shaw LC, Brown DP, Hollander EE, et al. Quantitative control of gene-engineered T-cell activity through the covalent attachment of targeting ligands to a universal immune receptor. J Am Chem Soc. 2020;142(14):6554–68.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Liu X, Wen J, Yi H, Hou X, Yin Y, Ye G, et al. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release. Ther Adv Med Oncol. 2020;12:1758835920910347.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lohmueller J, Butchy AA, Tivon Y, Kvorjak M, Miskov-Zivanov N, Deiters A, et al. Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting. bioRxiv. 2020. https://doi.org/10.1101/2020.01.17.909895.

    Article 

    Google Scholar     

  • Ruffo E, Kvorjak M, Adams E, Lohmueller J. Preclinical development of universal SNAP-CAR T cell therapy. J Immunol. 2021;206(Supplement):67.11.

    Article 

    Google Scholar     

  • Bachmann M. The UniCAR system: a modular CAR T cell approach to improve the safety of CAR T cells. Immunol Lett. 2019;211:13–22.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Koristka S, Cartellieri M, Arndt C, Bippes CC, Feldmann A, Michalk I, et al. Retargeting of regulatory T cells to surface-inducible autoantigen La/SS-B. J Autoimmun. 2013;42:105–16.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Nardi N, Brito-Zeron P, Ramos-Casals M, Aguilo S, Cervera R, Ingelmo M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sjogren’s syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol. 2006;25(3):341–6.

    Article 
    PubMed 

    Google Scholar     

  • Pan ZJ, Davis K, Maier S, Bachmann MP, Kim-Howard XR, Keech C, et al. Neo-epitopes are required for immunogenicity of the La/SS-B nuclear antigen in the context of late apoptotic cells. Clin Exp Immunol. 2006;143(2):237–48.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Malik S, Bruner GR, Williams-Weese C, Feo L, Scofield RH, Reichlin M, et al. Presence of anti-La autoantibody is associated with a lower risk of nephritis and seizures in lupus patients. Lupus. 2007;16(11):863–6.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Meyer JE, Loff S, Dietrich J, Spehr J, Jurado Jimenez G, von Bonin M, et al. Evaluation of switch-mediated costimulation in trans on universal CAR-T cells (UniCAR) targeting CD123-positive AML. Oncoimmunology. 2021;10(1):1945804.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Loff S, Dietrich J, Meyer JE, Riewaldt J, Spehr J, von Bonin M, et al. Rapidly switchable universal CAR-T cells for treatment of cd123-positive leukemia. Mol Ther Oncolytics. 2020;17:408–20.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wermke M, Kraus S, Ehninger A, Bargou RC, Goebeler ME, Middeke JM, et al. Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML. Blood. 2021;137(22):3145–8.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Bachmann D, Aliperta R, Bergmann R, Feldmann A, Koristka S, Arndt C, et al. Retargeting of UniCAR T cells with an in vivo synthesized target module directed against CD19 positive tumor cells. Oncotarget. 2018;9(7):7487–500.

    Article 
    PubMed 

    Google Scholar     

  • Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Arndt C, et al. Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells. Blood Cancer J. 2018;8(9):81.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Loureiro LR, Feldmann A, Bergmann R, Koristka S, Berndt N, Mathe D, et al. Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers. J Exp Clin Cancer Res. 2020;39(1):77.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Albert S, Arndt C, Feldmann A, Bergmann R, Bachmann D, Koristka S, et al. A novel nanobody-based target module for retargeting of T lymphocytes to EGFR-expressing cancer cells via the modular UniCAR platform. Oncoimmunology. 2017;6(4):e1287246.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Jureczek J, Feldmann A, Bergmann R, Arndt C, Berndt N, Koristka S, et al. Highly efficient targeting of EGFR-Expressing tumor cells with UniCAR T cells via target modules based on cetuximab((R)). Onco Targets Ther. 2020;13:5515–27.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Arndt C, Loureiro LR, Feldmann A, Jureczek J, Bergmann R, Mathe D, et al. UniCAR T cell immunotherapy enables efficient elimination of radioresistant cancer cells. Oncoimmunology. 2020;9(1):1743036.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pishali Bejestani E, Cartellieri M, Bergmann R, Ehninger A, Loff S, Kramer M, et al. Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model. Oncoimmunology. 2017;6(10):e1342909.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Feldmann A, Arndt C, Bergmann R, Loff S, Cartellieri M, Bachmann D, et al. Retargeting of T lymphocytes to PSCA- or PSMA positive prostate cancer cells using the novel modular chimeric antigen receptor platform technology “UniCAR.” Oncotarget. 2017;8(19):31368–85.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Mitwasi N, Feldmann A, Arndt C, Koristka S, Berndt N, Jureczek J, et al. “UniCAR”-modified off-the-shelf NK-92 cells for targeting of GD2-expressing tumour cells. Sci Rep. 2020;10(1):2141.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Feldmann A, Hoffmann A, Kittel-Boselli E, Bergmann R, Koristka S, Berndt N, et al. A novel revcar platform for switchable and gated tumor targeting. Blood. 2019;134(Supplement_1):5611. https://doi.org/10.1182/blood-2019-128436.

    Article 

    Google Scholar     

  • Feldmann A, Hoffmann A, Bergmann R, Koristka S, Berndt N, Arndt C, et al. Versatile chimeric antigen receptor platform for controllable and combinatorial T cell therapy. Oncoimmunology. 2020;9(1):1785608.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Kittel-Boselli E, Soto KEG, Loureiro LR, Hoffmann A, Bergmann R, Arndt C, et al. Targeting acute myeloid leukemia using the RevCAR platform: a programmable, switchable and combinatorial strategy. Cancers. 2021;13(19):4785.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Mitwasi N, Hassan H, Arndt C, Loureiro L, Neuber C, Kegler A, et al. 45P The RevCAR T cell platform: a switchable and combinatorial therapeutic strategy for glioblastoma. Immuno-Oncol Technol. 2022. https://doi.org/10.1016/j.iotech.2022.100150.

    Article 

    Google Scholar     

  • Cho JH, Collins JJ, Wong WW. Universal chimeric antigen receptors for multiplexed and logical control of T cell responses. Cell. 2018;173(6):1426-1438.e11.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Cho JH, Okuma A, Sofjan K, Lee S, Collins JJ, Wong WW. Engineering advanced logic and distributed computing in human CAR immune cells. Nat Commun. 2021;12(1):792.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Lajoie MJ, Boyken SE, Salter AI, Bruffey J, Rajan A, Langan RA, et al. Designed protein logic to target cells with precise combinations of surface antigens. Science. 2020;369(6511):1637–43.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Depil S, Duchateau P, Grupp SA, Mufti G, Poirot L. “Off-the-shelf” allogeneic CAR T cells: development and challenges. Nat Rev Drug Discov. 2020;19(3):185–99.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Caldwell KJ, Gottschalk S, Talleur AC. Allogeneic CAR cell therapy-more than a pipe dream. Front Immunol. 2020;11:618427.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Dimitri A, Herbst F, Fraietta JA. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Mol Cancer. 2022;21(1):78.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Park JJ, Lee KAV, Lam SZ, Tang K, Chen S. Genome engineering for next-generation cellular immunotherapies. Biochemistry. 2022. https://doi.org/10.1021/acs.biochem.2c00340.

    Article 
    PubMed 

    Google Scholar     

  • Naeem M, Hazafa A, Bano N, Ali R, Farooq M, Razak SIA, et al. Explorations of CRISPR/Cas9 for improving the long-term efficacy of universal CAR-T cells in tumor immunotherapy. Life Sci. 2023;316:121409.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Zhang H, Yu P, Tomar VS, Chen X, Atherton MJ, Lu Z, et al. Targeting PARP11 to avert immunosuppression and improve CAR T therapy in solid tumors. Nat Cancer. 2022;3(7):808–20.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Uckun FM. Overcoming the immunosuppressive tumor microenvironment in multiple myeloma. Cancers. 2021;13(9):2018.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Chung H, Jung H, Noh JY. Emerging approaches for solid tumor treatment using CAR-T cell therapy. Int J Mol Sci. 2021;22(22):12126.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Wang Z, McWilliams-Koeppen HP, Reza H, Ostberg JR, Chen W, Wang X, et al. 3D-organoid culture supports differentiation of human CAR(+) iPSCs into highly functional CAR T cells. Cell Stem Cell. 2022;29(4):515-527.e8.

    Article 
    PubMed 

    Google Scholar     

  • Yang Y, Bi X, Gergis M, Yi D, Hsu J, Gergis U. Allogeneic chimeric antigen receptor T cells for hematologic malignancies. Hematol Oncol Stem Cell Ther. 2022;15(3):112–6.

    PubMed 

    Google Scholar     

  • Demel I, Koristek Z, Motais B, Hajek R, Jelinek T. Natural killer cells: Innate immune system as a part of adaptive immunotherapy in hematological malignancies. Am J Hematol. 2022;97(6):802–17.

    Article 
    CAS 
    PubMed 

    Google Scholar     

  • Lee D, Rosenthal CJ, Penn NE, Dunn ZS, Zhou Y, Yang L. Human gammadelta T cell subsets and their clinical applications for cancer immunotherapy. Cancers. 2022;14(12):3005.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Pan K, Farrukh H, Chittepu V, Xu H, Pan CX, Zhu Z. CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy. J Exp Clin Cancer Res. 2022;41(1):119.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Rossi F, Fredericks N, Snowden A, Allegrezza MJ, Moreno-Nieves UY. Next generation natural killer cells for cancer immunotherapy. Front Immunol. 2022;13:886429.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Urbanska K, Lynn RC, Stashwick C, Thakur A, Lum LG, Powell DJ Jr. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells. J Transl Med. 2014;12:347.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Karches CH, Benmebarek MR, Schmidbauer ML, Kurzay M, Klaus R, Geiger M, et al. Bispecific antibodies enable synthetic agonistic receptor-transduced T cells for tumor immunotherapy. Clin Cancer Res. 2019;25(19):5890–900.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Thakur A, Scholler J, Kubicka E, Bliemeister ET, Schalk DL, June CH, et al. Bispecific antibody armed metabolically enhanced headless CAR T cells. Front Immunol. 2021;12:690437.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Grada Z, Hegde M, Byrd T, Shaffer DR, Ghazi A, Brawley VS, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2(7):e105.

    Article 
    PubMed 
    PubMed Central 

    Google Scholar     

  • Li D, Hu Y, Jin Z, Zhai Y, Tan Y, Sun Y, et al. TanCAR T cells targeting CD19 and CD133 efficiently eliminate MLL leukemic cells. Leukemia. 2018;32(9):2012–6.

    Article 
    PubMed 

    Google Scholar     

  • Khan AN, Chowdhury A, Karulkar A, Jaiswal AK, Banik A, Asija S, et al. Immunogenicity of CAR-T cell therapeutics: evidence, mechanism and mitigation. Front Immunol. 2022;13:886546.

    Article 
    CAS 
    PubMed 
    PubMed Central 

    Google Scholar     

    • Posted on

    Car Tuning Market : An In-Depth Look at the Current State and Future Outlook

    Car Tuning Market : An In-Depth Look at the Current State and Future Outlook
    Emergen Research Logo

    Emergen Research Logo

    Rising demand for high-performance vehicles, coupled with growing utilization of car tuning services, is expected to boost market growth

    Increasing use of automotive tuning & repair services and rising demand for high-performance vehicles are among the major factors driving market revenue growth. ”

    — Emergen Research

    VANCOUVER, BC, CANADA, February 2, 2023 /EINPresswire.com/ — The latest report, titled ‘Global Car Tuning Market,’ comprises a profound analysis of the fundamental parameters contributing to the global Car Tuning market scenario. Increasing use of automotive tuning & repair services and rising demand for high-performance vehicles are among the major factors driving market revenue growth. Over recent years, boom in automobile production and sales, rising disposable incomes of the population, growing demand for luxury sports cars such as crossover SUVs, especially among car enthusiasts, and advances in car tuning techniques have driven market revenue growth to a significant extent. Car tuning, also referred to as automotive tuning, is the process of modifying a car to improve its performance based on specific user needs. Tuning improves engine function and provides better fuel economy and torque to the vehicle, enhancing its overall performance. Generally, car tuning involves the addition, replacement, or alteration of various automotive parts and systems. It thus helps to increase the vehicle’s power output and enhances its appearance altogether.

    The research report provides the reader with an in-depth interpretation of the Car Tuning market dynamics, including the crucial drivers, opportunities, threats, and challenges. The report also describes the key business strategies, demand and supply ratios, leading regions, and the renowned market players, in a nutshell, offering a futuristic outlook of the overall Car Tuning industry. The market intelligence report is a prototype of the 360° overview of the global Car Tuning industry, shedding light on the estimated market value, share, growth trends, gross revenue, competitive overview, prominent manufacturers and buyers, available product types, and end-use applications.

    To Receive A PDF Sample Of The Report, Visit @https://www.emergenresearch.com/request-sample/795

    Competitive Terrain:

    The global Car Tuning industry is highly consolidated owing to the presence of renowned companies operating across several international and local segments of the market. These players dominate the industry in terms of their strong geographical reach and a large number of production facilities. The companies are intensely competitive against one another and excel in their individual technological capabilities, as well as product development, innovation, and product pricing strategies.

    The Leading Market Contenders Listed In The Report Are:

    Derive Systems, COBB Tuning, Alientech SRL, Roo Systems, EFI Live, Magic Motorsports, Edge Products LLC, Diablo Sport, Mountune, Autotuner, AEM Electronics Inc., Hypertech Inc., HP Tuners, Flashtec SA, Jet Performance Products Inc., Layton Remaps & Performance, EcuTek Technologies Ltd., TuneOTronics, Turbo Dynamics Ltd., RS Tuning Limited, Tuning Works

    Some Key Highlights in the Report:

    Among vehicle type segments, the global car tuning market is segmented into passenger vehicles, light commercial vehicles, and heavy commercial vehicles. The passenger vehicles segment is expected to reach the largest market share over the forecast period due to favorable factors. Rise in production and sales of passenger vehicles globally, increasing demand for car tuning and engine remapping services, expanding transportation & logistics sector, and growing need for high-performance vehicles are among the major factors boosting the growth of this segment.

    Based on modification area, the global car tuning market is segmented into audio, interior, body tuning, engine tuning, suspension tuning, tires, and others. The engine tuning segment is expected to dominate other segments with the fastest revenue growth rate during the forecast period. Growth of this segment is mainly attributed to rising need for dynamic vehicle performance and improved fuel-efficiency, increasing use of engine tuning and remapping solutions such as chip installation, OBD (on-board diagnostics) tuning, tuning boxes, and advanced ECU remapping, and emergence of highly advanced engine tuning techniques such as EFI (electronic fuel injection) and EEPROM reprogramming.

    North America was the most dominant regional market in the global car tuning market in 2020, accounting for the largest revenue share. Primary factors driving the revenue growth of this regional market are rapid adoption of advanced automotive technologies, rising focus on improving vehicle power and fuel economy, increasing use of automotive tuning & remapping services among car enthusiasts, and presence of top industry players such as COBB Tuning, Derive Systems, and AEM Electronics Inc., in the region.

    To Get A Discount On The Latest Report, Visit @https://www.emergenresearch.com/request-discount/795

    For the purpose of this report, the global car tuning market is segmented on the basis of fuel type, vehicle type, modification area, tuning stage, sales channel, and region:

    Fuel Type Outlook (Revenue, USD Million; 2018–2028)

    Gasoline

    Diesel

    Vehicle Type Outlook (Revenue, USD Million; 2018–2028)
    Passenger Vehicles

    Light Commercial Vehicles

    Heavy Commercial Vehicles

    Modification Area Outlook (Revenue, USD Million; 2018–2028)

    Audio

    Interior

    Body Tuning

    Engine Tuning

    Suspension Tuning

    Tires

    Others

    Regional Segmentation:

     

    North America

    Latin America

    Europe

    Middle East & Africa

    Asia Pacific

    Browse Detailed Research Report @https://www.emergenresearch.com/industry-report/car-tuning-market

    Report Highlights:

    Besides offering a vivid depiction of the global Car Tuning business sphere and its fundamental operations, the latest report provides the industrial chain analysis and list down the current and future market trends and growth opportunities.

    The report includes information on the present and historical market scenarios, which helps forecast the market conditions over the next eight years (2020-2028).

    The report scrutinizes the salient factors influencing the growth of the market in the near future.

    The strategic marketing recommendations, crucial information related to the new market entrants, and expansion plans of various businesses are poised to provide the reader with a competitive edge in the market.

    Key Benefits of the Report:

    Comprehensive analysis of the competitive scenario and its changing dynamics

    Analytical data with detailed SWOT analysis and Porter’s Five Forces analysis

    In-depth 8 year analysis of the Global Car Tuning Market

    Critical assessment of the key market segments

    Comprehensive analysis of the drivers, restraints, trends, and opportunities

    Detailed regional analysis and extensive company profiling

    Extensive assessment of current and emerging trends of the market

    Buy Now: @https://www.emergenresearch.com/purchase-enquiry/795

    Browse More Report By Emergen Research:

    Martech Market

    https://www.emergenresearch.com/industry-report/martech-market

    Cyberbiosecurity Market

    https://www.emergenresearch.com/industry-report/cyberbiosecurity-market

    Lead Free Piezoelectric Ceramic Material Market

    https://www.emergenresearch.com/industry-report/lead-free-piezoelectric-ceramic-material-market

    Computer Aided Design Market

    https://www.emergenresearch.com/industry-report/computer-aided-design-market

    Business Intelligence And Analytics Platforms Market

    https://www.emergenresearch.com/industry-report/business-intelligence-and-analytics-platforms-market

    Automotive Fuel Injection Systems Market

    https://www.emergenresearch.com/industry-report/automotive-fuel-injection-systems-market

    Intelligent Building Automation Technologies Market

    https://www.emergenresearch.com/industry-report/intelligent-building-automation-technologies-market

    Smart Building Sensors Market

    https://www.emergenresearch.com/industry-report/smart-building-sensors-market

    Radiation Hardened Electronics Market

    https://www.emergenresearch.com/industry-report/radiation-hardened-electronics-market

    Immunocytokines Market

    https://www.emergenresearch.com/industry-report/immunocytokines-market

    About Emergen Research

    Emergen Research is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target, and analyze consumer behavior shifts across demographics, across industries, and help clients make smarter business decisions. We offer market intelligence studies ensuring relevant and fact-based research across multiple industries, including Healthcare, Touch Points, Chemicals, Types, and Energy. We consistently update our research offerings to ensure our clients are aware of the latest trends existent in the market. Emergen Research has a strong base of experienced analysts from varied areas of expertise. Our industry experience and ability to develop a concrete solution to any research problems provides our clients with the ability to secure an edge over their respective competitors.

    Eric Lee
    Emergen Research
    +91 90210 91709
    sales@emergenresearch.com
    Visit us on social media:
    Facebook
    Twitter
    LinkedIn

    Car Tuning Market: A Comprehensive Overview of the Industry’s Players and Trends

    You just read:


    EIN Presswire’s priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content.
    As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone’s Internet News Presswire™,
    tries to define some of the boundaries that are reasonable in today’s world. Please see our
    Editorial Guidelines
    for more information.

    Submit your press release

    Posted on

    This BMW i4 Aftermarket Police Car Promotes Street-Legal Tuning in Germany

    This BMW i4 Aftermarket Police Car Promotes Street-Legal Tuning in Germany

    A new BMW i4 law enforcement vehicle aims to boost tuning methods that are lawful on the streets of Germany.

    The automobile is the get the job done of tuning household AC Schnitzer, as claimed by Motor1. Centered in the city of Aachen, AC Schnitzer has a background of manufacturing automobiles for German legislation enforcement. The new all-electric BMW i4 establish marks the eighth police auto the enterprise has created. Like so lots of other German tuning models, the firm prides alone on protecting street-legal, TUV-permitted position for the modification components that it sells. (TUV is the German authority that specials with basic safety inspections for roadgoing automobiles.)

    The motor vehicle features a total aerodynamics package deal. It gets a good front spoiler additional, with aero things also extra to the vents on possibly facet of the basic BMW kidney grilles. There is also a rear roof and trunk lid spoiler, way too, along with several aero trim pieces on the sides of the car. Notably, although, the i4 does not feature any effectiveness drivetrain modifications. Dependent on the i4 M50 Gran Coupe, it features 536 horsepower from a twin-motor process that drives all four wheels. It is really great for a zero-to-60-mph dash in just 3.9 seconds.

    The i4 has been reduced, also. A spring kit drops the experience height by somewhere around an inch in contrast to the showroom product. This aids managing, in unique by decreasing the vehicle’s heart of gravity. In accurate German fashion, the dealing with upgrades ended up examined and validated on the Nürburgring. The suspension updates are paired with a established of AC Schnitzer circulation-fashioned 20-inch wheels with a break up 5-spoke design.

    Further than the moderate effectiveness upgrades, the car or truck functions Hella police lights on top rated and unique safety movie window treatment plans. The interior is not still left out, getting a set of aluminum pedals and linked trim. The i4 shown on the infotainment system has also been up-to-date with a police livery to match the vehicle’s true exterior.

    The automobile was created for the Tune It! Risk-free! campaign, which is run by the Federal Ministry of Transportation and Digital Infrastructure in Germany. The campaign has been jogging for the past 17 many years and consists of organizations developing tuned vehicles that are thoroughly compliant with Germany’s rigorous on-road polices. For police, it serves as a way to persuade enthusiasts to engage in by the rules. For sponsors, which finance the method, it serves as a way to showcase their assortment of avenue-lawful tuning merchandise.

    https://www.youtube.com/look at?v=tOV1J7UFDWM

    It’s an interesting glance at the way the German automotive culture works. We often see tuners and authorities companies at loggerheads in the United States. In Germany, the tight regulatory ecosystem and regular vehicular inspections have spurred an ethos of collaboration fairly than confrontation. Whether or not you assistance the independence to pursue wild modifications, or you consider in tightly regulating tuning for road basic safety causes, there are arguments to be produced in favor of either approach.

    Received a suggestion? Allow the author know: lewin@thedrive.com